This HTML5 document contains 24 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n13https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
dbchttp://dbpedia.org/resource/Category:
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Alzheimer's_Disease_Cooperative_Study
rdfs:label
Alzheimer's Disease Cooperative Study
rdfs:comment
The Alzheimer's Disease Cooperative Study (ADCS) was founded at University of California San Diego in 1991 and coordinates clinical trials of candidate treatments for Alzheimer's disease. It is funded by the National Institutes of Health as well as companies that develop drugs. As of 2008, 75 research sites in the United States and Canada were part of the consortium. served as director until February 2007, when he died; Paul Aisen was recruited to succeed him. In 2006, the NIH awarded $52 million to ADCS to fund 6 years of further clinical trials.
dcterms:subject
dbc:Alzheimer's_disease
dbo:wikiPageID
54305915
dbo:wikiPageRevisionID
1110282956
dbo:wikiPageWikiLink
dbr:Eli_Lilly_and_Company dbr:University_of_California_San_Diego dbr:Leon_Thal dbr:Alzheimer's_disease dbr:Solanezumab dbr:Paul_Aisen dbr:Amazon_Web_Services dbc:Alzheimer's_disease dbr:National_Institutes_of_Health
owl:sameAs
n13:2pJWu wikidata:Q30315196
dbp:wikiPageUsesTemplate
dbt:Reflist
dbo:abstract
The Alzheimer's Disease Cooperative Study (ADCS) was founded at University of California San Diego in 1991 and coordinates clinical trials of candidate treatments for Alzheimer's disease. It is funded by the National Institutes of Health as well as companies that develop drugs. As of 2008, 75 research sites in the United States and Canada were part of the consortium. served as director until February 2007, when he died; Paul Aisen was recruited to succeed him. In 2006, the NIH awarded $52 million to ADCS to fund 6 years of further clinical trials. In 2013 Eli Lilly committed to spending $76.6 million on clinical trials through the center. The center has coordinated important clinical trials on AD drugs like solanezumab. Aisen left UCSD in 2015 because he was unhappy with the level of support that UCSD was providing him and due to USC's offer. UCSD and USC ended up in litigation over control of the ADCS and its research data, which at that time involved six ongoing clinical trials and data collected on thousands of clinical trial subjects. Part of the dispute arose because Aisen's lab had uploaded the data from the ADCS onto Amazon Cloud servers and would not give the passwords to UCSD officials. Some aspects of data management were temporarily settled in 2016; as of 2017 the litigation was ongoing. The lawsuit was settled in 2019.
prov:wasDerivedFrom
wikipedia-en:Alzheimer's_Disease_Cooperative_Study?oldid=1110282956&ns=0
dbo:wikiPageLength
4996
foaf:isPrimaryTopicOf
wikipedia-en:Alzheimer's_Disease_Cooperative_Study
Subject Item
dbr:Keck_School_of_Medicine_of_USC
dbo:wikiPageWikiLink
dbr:Alzheimer's_Disease_Cooperative_Study
Subject Item
dbr:Paul_Aisen
dbo:wikiPageWikiLink
dbr:Alzheimer's_Disease_Cooperative_Study
Subject Item
wikipedia-en:Alzheimer's_Disease_Cooperative_Study
foaf:primaryTopic
dbr:Alzheimer's_Disease_Cooperative_Study